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Abstract: Chronic lower back pain is a significant disease that affects nearly 20% of the 
worldwide population. Along with hindering patients’ quality of life, chronic lower back pain 
is considered to be the second most common cause of disability among Americans. Treating 
chronic lower back pain is often a challenge for providers, especially in light of our current 
opioid epidemic. With this epidemic and an increased aging population, there is an imminent 
need for development of new pharmacologic therapeutic options, which are not only effective 
but also pose minimal adverse effects to the patient. With these considerations, a novel thera-
peutic agent called tanezumab has been developed and studied. Tanezumab is a humanized 
monoclonal immunoglobulin G2 antibody that works by inhibiting the binding of NGF to its 
receptors. NGF is involved in the function of sensory neurons and fibers involved in nociceptive 
transduction. It is commonly seen in excess in inflammatory joint conditions and in chronic pain 
patients. Nociceptors are dependent on NGF for growth and ongoing function. The inhibition 
of NGF binding to its receptors is a mechanism by which pain pathways can be interrupted. In 
this article, a number of recent randomized controlled trials are examined relating to the efficacy 
and safety of tanezumab in the treatment of chronic lower back pain. Although tanezumab was 
shown to be an effective pain modulator in major trials, several adverse effects were seen among 
different doses of the medication, one of which led to a clinical hold placed by the US Food 
and Drug Administration. In summary, tanezumab is a promising agent that warrants further 
investigation into its analgesic properties and safety profile.
Keywords: tanezumab, monoclonal antibody, chronic lower back pain, neurotrophin nerve 
growth factor (NGF), tropomyosin receptor A (TrkA), treatment
Introduction
Chronic lower back pain is common and is associated with a significant burden of ill-
ness. The Centers for Disease Control and Prevention lists back pain as the second most 
common cause of disability among American adults.1,2 A 2015 large, multinational epi-
demiological estimate of global burden of illness reported low back and neck pain as the 
leading cause of disability.3 In 2015, lower back pain was thought to affect 18.5% (16.4%–
20.9%) of the worldwide population and was associated with significant disability.3 In 
countries sampled, representative of all continents, back pain was the most common 
cause of disability in all regions except those of Sub-Saharan Africa where human 
immunodeficiency virus (HIV) and hematological disorders were most disabling.3
Back pain was associated with 30 million person-years lost to disability in 2015 
alone.3 Despite many advances, this global, disabling disease has remained the com-
monest cause of years lost to disability (YLD) since 1990. The population rates of 
lower back pain have remained relatively constant over interval assessments at 1990, 
2005, and 2015. Owing to its management chiefly in primary care, and thus potentially 
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outside of formalized registries, the incidence and thus esti-
mates of disability may be falsely low.3
Musculoskeletal disease, including lower back pain, 
remains the leader in YLD across socioeconomic strata, and 
its occurrence was more prominent with increasing socioeco-
nomic score.3 In most socioeconomic groups, the prevalence 
of the disease exceeds what is expected via epidemiological 
model. This rise is most noticeably evident in the highest of 
socioeconomic strata and particularly in women.
Given an increase in aging population, the rate of back 
pain and corresponding disability is likely to rise. It has 
been observed that slight increases have occurred in back 
pain-related YLD in older patients from 1990 to 2015, sug-
gesting that people are living longer but are increasingly 
disabled at the same time.3 This is a threat to healthy aging, 
of which mobility is a basic component. These data have 
implications for global health in the broadest sense. Inter-
estingly, lower back pain typically becomes apparent as a 
disability in adolescents and young adults (age 15–39).3 Peak 
prevalence of lower back pain is thought to occur between 
the ages of 35 and 55.4
In addition to the disability and quality of life burden of 
lower back pain, an economical burden must also be consid-
ered. Individuals, their families, employers, and governments 
all face costs associated with back pain. Various estimates 
have been calculated from around the world, but all sug-
gest a significant figure annually accrued by this condition. 
A study from the United Kingdom estimated 100 million 
work days lost per year.5 The US estimates from 2007 suggest 
that 100–200 billion dollars and 149 million workdays are 
lost per year due to lower back pain.6 The bulk of cost comes 
from loss of productivity or absence from work. It is worth 
noting that some analyses have demonstrated that a small 
fraction of back pain sufferers (5%) account for ~75% of 
the costs associated with lower back pain.7
Lower back pain is a common, disabling global affliction 
that has remained problematic for many decades despite 
advances in pharmacological and physical treatment and 
their availability. The effective treatment of lower back pain 
has global implications in economical terms of productive 
working years as well as quality of life.
Pharmacology
General
Tanezumab is a humanized monoclonal immunoglobulin 
G2 antibody against the neurotrophin NGF. NGF regulates 
the growth and function of sensory neurons, including small 
diameter afferent fibers involved in nociceptive transduction. 
This drug has an analgesic effect related to its inhibition of 
peripheral nociception. Tanezumab has shown promise and 
efficacy in the management of pain via the drug’s ability to 
inhibit the interaction between NGF and TrkA and p75.8
Mechanism of action
Tanezumab’s primary effect is to inhibit the interaction 
between NGF and its high affinity receptor TrKA and 
low-affinity receptor p75. The TrKA is a tyrosine kinase 
receptor, while p75 is a specific receptor for the NGF ligand.9 
Peripheral nociceptive fibers and nociceptors, rich in p75 
and TrKA receptors, are dependent upon NGF for both 
genesis and ongoing function.9 Nociceptor development is 
dependent upon NGF. Pain processing is heavily reliant on 
the presence of NGF, particularly in “C” fibers. These are 
small unmyelinated fibers that synthesize and secrete the 
neurotransmitter substance P and calcitonin gene-related 
peptide (CGRP). These “C” fibers have been implicated in 
both acute and chronic pain.9
Tanezumab binds to human NGF with high affinity, 
having a dissociation constant of less than 2 Pm.9 The IC50 
of tanezumab is 20 Pm, which is roughly equivalent to the 
EC50 of NGF for TrKA and t75.9
 While tanezumab has been shown to bind tightly to NGF, 
it is highly selective with a relative 1000-fold decrease in 
affinity for other substances in the NGF family, specifically 
BDNF, NT-3 or NT-4/5, NTF, GDNF, and VEGF.9
An excess of NGF is associated with inflammatory joint 
conditions and is critical in the etiology of chronic pain. 
Chronic stimulation of peripheral nociceptors and firing 
of C type fibers is thought to be part of the underpinning of 
central sensitization, hyperalgesia, and allodynic aspects of 
chronic pain.10
Pharmacokinetics
Related to the mechanism of action of monoclonal antibodies, 
the pharmacokinetics of these drugs are complex and exhibit 
both linear and nonlinear kinetics.11 Pharmacokinetic assess-
ment of tanezumab was initially performed as a dose-finding 
experiment early in drug development with these data sug-
gesting a 2-compartment model with linear elimination 
kinetics.12 The pharmacokinetics have been further analyzed 
from assays taken in Phase III trials.12 In a 2-compartment 
model investigation, a mixed linear/nonlinear elimination 
model was developed.12 This model was based on a “typical” 
study patient in Phase III trials – an 85 kg female patient with 
normal renal function (creatinine clearance 93.5 mL/min). 
Initial volume of distribution (Vd) was estimated at 2.71 L 
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(approximating plasma volume) with Vd at steady state 
of 4.69 L.12
The elimination of tanezumab is via endocytosis and 
catabolism in the reticuloendothelial system. Scavenging 
of the antibody from this system prolongs elimination and 
thus can alter elimination kinetics. As would be expected, 
clearance models for tanezumab differ for linear vs non-
linear models (Clearance 0.135 L/day vs 0.207 L/day); but 
this effect is small and is only relevant for small doses of 
tanezumab (2.5 mg).12 The low total clearance is manifest 
as residual plasma tanezumab up to and including 8 weeks 
after dosing.
Nonlinear kinetics is postulated to be related to the 
interaction of the monoclonal antibody with its target 
and the formation of multimers and the internalization of 
tanezumab-NGF receptor complexes. Free drug clearance 
is estimated at 100 L/day. This estimate comes from other 
monoclonal antibody research data and the high capacity 
function of the reticuloendothelial system.12 Elimination 
half-life of tanezumab is 21 days, which is typical of other 
monoclonal antibodies.13
Females exhibited slower elimination of the drug, and 
this is possibly related to hormone- and sex-based differ-
ences in receptor expression and bulk.12 Renal dysfunction 
appears to have a significant effect on total body clearance 
of tanezumab.12 This is unexpected, given the relative per-
meability of the glomerulus to monoclonal antibodies and 
it is suspected to be related to transcytosis.14 Body weight 
has the largest impact on total body clearance with a 10% 
increase in weight, resulting in a 10% increase in clearance; 
however this variation has not been explained. Drug dosing 
has a minimal effect on clearance and exhibits no effect at 
all on weight-based or fixed dose serum tanezumab levels at 
their maximum levels following initial infusion. This finding 
is consistent with infusion of other drugs of this class.15
Efficacy and safety
Tanezumab has been primarily studied for its analgesic 
efficacy in the treatment of three major conditions: cystitis, 
osteoarthritis (OA), and chronic lower back pain. There is a 
small volume of work revolving around its use as a cancer 
pain agent, but there are few Phase III trials with data for 
this indication. The bulk of the efficacy data for tanezumab 
is from its use as an analgesic in OA of the hip and knee. 
Initially, the drug was favorably received for this indica-
tion; however, safety data reviewed in 2010 suggested that 
its use was associated with osteonecrosis (ON) of affected 
joints.16 The US Food and Drug Administration (FDA) issued 
a research hold on the drug at this time for all indications 
other than that for cancer pain. A formal review in 2012 
analyzed the reported 87 cases of ON, with 81 cases reported 
from Phase III OA trails and 6 from Phase II chronic lower 
back pain trials. It was determined that there were in fact 
only two cases of ON and both were from OA trials. These 
events were deemed to be primarily due to worsening OA, 
with rapid progression of osteoarthritis (RPOA) as a less 
common cause. The pathological changes were thought to 
occur due to the analgesia from tanezumab, prostaglandin 
paucity-mediated bone destruction from co-prescribed 
non-steroidal anti-inflammatory drugs, and poor underlying 
bone architecture rather than a primary drug-related effect 
on bone matrix.16,17
With regard to clinical efficacy and safety of tanezumab 
in lower back pain, three randomized controlled trials and 
one meta-analysis including tanezumab trials are available 
for analysis. In 2011 Katz et al analyzed efficacy and safety 
of tanezumab.18 This was a proof-of-concept, three-parallel 
arm, prospective, placebo/active-controlled, double-blind, 
randomized controlled trial of 217 patients with chronic 
lower back pain. The study’s primary outcome was aver-
age lower back pain (aLBP) intensity score, and secondary 
outcomes included proportional aLBP decrement, global 
assessments of disability, and concomitant analgesic use. 
Patients enrolled were non-morbidly obese adults with non-
radicular, non-traumatic Quebec Task Force category 1 or 2 
lower back pain requiring the chronic use of simple and mild 
opiate analgesics. Patients underwent washout and baseline 
assessments and were then randomized to receive either a) 
tanezumab infusion 200 mcg/kg + tablet placebo, b) naproxen 
1 g/day + infusion placebo, or c) infusion and placebo tablet. 
Follow-up consisted of safety and efficacy measures for 16 
weeks, with efficacy at 6 weeks being the primary end point.18 
The study had high attrition from dropout/loss to follow-up, 
and only 67%, 73%, and 61% of patients in the respective 
tanezumab, naproxen, and placebo arms completed the 
study.18 The baseline demographics among the groups were 
nonheterogenous. All patients included in the analysis dem-
onstrated the efficacy of treatment irrespective of cohort. At 
6 weeks, there was a statistically significant improvement 
in aLBP in the tanezumab group vs both other cohorts. This 
held true for secondary endpoints as well.18
Safety data were collected, and adverse effect rates 
were similar among the groups. Nine patients discontinued 
the trial related to adverse effects. This was dispropor-
tionately weighted to the placebo and tanezumab group 
(4.9% and 4.5% of patients respectively). Adverse effects 
Therapeutics and Clinical Risk Management 2018:14
Table 1 Comparison of average lower back pain intensity scores









Baseline mean (SD) 6.74 (1.48) 6.57 (1.39) 6.62 (1.36) 6.77 (1.38) 6.71 (1.37)
LS mean change (Se) -2.18 (0.14) -2.06 (0.14) -1.58 (0.16) -1.66 (0.114) -1.25 (0.16)
P-value vs placebo 0.001 0.001 0.113 0.037
P-value vs naproxen 0.006 0.035 0.688
Notes: Low back intensity scores are rated on a scale of 0–10. Data from Kivitz et al.19





were uniformly nonserious, with 5% or more of patients 
who received  tanezumab reporting arthralgia, headache, 
hyperesthesia, and myalgia. Feelings of abnormal peripheral 
sensation were reported in the tanezumab, naproxen, and 
placebo groups at 12.5%, 3.4%, and 2.4%, respectively. 
None of these complaints resulted in discontinuation of the 
study drug, all patients had normal neurological examina-
tions, and all hyperesthesia resolved within the 16-week 
study window. It should also be noted that in this study there 
were no severe adverse reactions reported in the tanezumab 
group. The study team concluded that tanezumab was an 
efficacious analgesic over 16 weeks in the treatment of lower 
back pain and had a similar rate of adverse effects to that of 
naproxen and placebo.18 This study was of a small sample 
size and employed an intention to treat strategy. Statistical 
analysis was unusual in that an alpha of 0.1 was accepted as 
statistically significant. The study also endured a high rate 
of attrition, though it was for all groups. The study had a 
short duration and a single infusion of tanezumab, so safety 
data may be incomplete.
In 2013 Kivitz et al published a similar, but larger study 
regarding the efficacy and safety of tanezumab. This time 
the authors compared differing doses of tanezumab to 
naproxen and placebo in concurrent arms.19 Study inclusion 
and exclusion criteria were nearly identical to those of Katz 
et al. Again, a washout period occurred, and patients had 
baseline measures taken and were subsequently randomized 
to receive either placebo, tanezumab 5 mg, 10 mg, or 20 mg, 
or naproxen in a double-blind, double-dummy fashion. Infu-
sions took place at weeks 1 and 8, and naproxen/placebo was 
given daily. This study enlisted 1,347 subjects, and patients 
were randomized into placebo, tanezumab 5 mg, 10 mg, or 
20 mg, or naproxen groups. Efficacy was measured via aLBP 
daily (Table 1) from baseline to week 16, and much like that 
of Katz et al, secondary measures of incremental changes of 
lower back pain, and global assessments of function (Table 2) 
and satisfaction, and rescue analgesia were employed. Safety 
was measured by assessment of any serious or nonserious 
adverse effects adjudicated by external clinicians. Statistical 
significance was set at the more traditional alpha of 0.05, and 
intention to treat was employed.
Baseline demographics and medical comorbidities were 
equivalent among groups. In this study, 20 mg and 10 mg tan-
ezumab were statistically significantly more efficacious than 
placebo and naproxen for the primary endpoint along with 
two additional pain-related secondary endpoints. It is worth 
noting that 20 mg tanezumab had little additional analgesic 
effect over the 10 mg dose. The 5 mg dose of tanezumab 
had no statistically significant effect vs naproxen or placebo. 
Pain-related efficacy and global assessments of function were 
improved with the higher doses of study drug right out to 
the 16-week mark. Adverse effects were most common in 
the tanezumab groups. In the 20 mg dose group, 64.4% of 
patients experienced an adverse event, which is compared 
with 52% in the placebo group, 60.8% with tanezumab 5 mg, 
58% with the 10 mg dose, and 48.1% in the naproxen group. 
Neurological sequelae, including paresthesia and headache, 
as well as arthralgia were the most common complaints and 
appeared to be dose dependent. Gastrointestinal adverse 
effects were reported in the tanezumab group at 12.1%, 8.8%, 
and 9.1% for the 5 mg, 10 mg, and 20 mg doses, respectively, 
and 10% in those treated with placebo. The highest rate of 
reported gastrointestinal adverse effects was in the naproxen 
group at 14.6%. Higher dose tanezumab was associated with 
hyperesthesia and dysesthesia at a rate of 12.9%, which far 
exceeded smaller doses, naproxen, or placebo. These events 
subsided by the end of the trial follow-up. Serious adverse 
effects were rare, but occurred more commonly in those 
receiving tanezumab; of note, none of the effects included 
ON, and there were no reported deaths in any groups.19
The study committee deemed these findings to demonstrate 
the efficacy and safety of tanezumab at the 10 mg and 20 mg 
doses compared to naproxen or placebo. Clinically meaning-
ful pain relief was estimated to be a reduction in pain scores 
of ~30%, and this was achieved in the 10 and 20 mg tanezumab 
dose groups. They found that the rates of adverse effects and 
patient attrition, which were again high, were not dissimilar to 
other trials of therapy for chronic lower back pain.19
Therapeutics and Clinical Risk Management 2018:14
Table 2 Comparison of Roland Morris Disability Questionnaire scores









Baseline mean (SD) 13.00 (4.97) 12.98 (5.11) 12.24 (4.92) 12.86 (4.93) 12.79 (4.74)
LS mean change (Se) -2.80 (0.26) -3.18 (0.26) -2.37 (0.29) -2.07 (0.26) -1.75 (0.29)
P-value vs placebo 0.006 0.001 0.125 0.405
P-value vs naproxen 0.042 0.002 0.428
Notes: Roland Morris Disability Questionnaire scores range from 0 to 2 with lower scores associated with better function. Data from Kivitz et al.19
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This larger trial demonstrated statistically and clinically 
significant analgesic effects of tanezumab and elucidated 
some potential therapeutic dosing regimens. The percentage 
of patients that responded to treatment were consistently 
higher in the tanezumab 10 mg and 20 mg arms compared to 
both naproxen and placebo arms. The overall safety profile 
of tanezumab was similar to other trials and similar to both 
placebo and naproxen treatment groups.19
A follow-up safety analysis subset of the Kivitz et al trial 
was performed by Gimbel et al in 2014.20 In this trial, those 
who completed the initial trial were then enrolled in a further 
noncontrolled, dose-blinded study in which 10 mg or 20 mg 
tanezumab intravenous (three doses) and subcutaneous (four 
doses) were given at 8-week intervals. This “add-on” study 
sought to determine the long-term efficacy of the drug. The 
primary endpoint of efficacy was measured by the change 
in reporting of Brief Pain Inventory Short Form. Secondary 
measures were global assessments of function and well-being, 
as previously used in the Kivitz et al study. Safety was also 
assessed in a similar fashion to previous studies with adverse 
effects being monitored for in each of the groups.
Those who remained in the trial to its completion were 
to undergo 64 weeks of additional treatment in an exten-
sion study. A total of 849 patients were randomized 2:1 
(20 mg:10 mg). Baseline demographics of the patients 
included were nonheterogeneous among the two study arms. 
The study was terminated early, but prior to its termination, 
the two groups received an average of 270 days (10 mg) and 
259 days (20 mg) of treatment.
Either dose of tanezumab was associated with a pain 
improvement compared to those who had been in the 
naproxen, 5 mg tanezumab, or placebo group initially. There 
was no further improvement of score seen in those who 
had previously taken tanezumab at the 10 or 20 mg dose. 
There was no statistically significant difference in efficacy 
between the 10 and 20 mg arms of the extension studies. 
Secondary markers of well-being were sustained in those 
taking tanezumab, but there was no further improvement in 
the secondary trial.
The trial was discontinued for safety reasons at the 
sponsors’ request. The reason for early termination was related 
to a partial clinical hold enacted by the FDA over joint safety. 
Tanezumab at the 20 mg dose was associated with more 
adverse outcomes than the 10 mg dose, (70.2% and 61.7% 
respectively). Parasthesias and neurological sequelae were 
again the most common complaints. Most adverse effects were 
considered non-serious, but serious adverse effects occurred 
in 4.7% (10 mg) and 4.6% (20 mg). The most serious adverse 
effect was OA requiring urgent joint replacement (six patients 
total; four patients took 20 mg and two took 10 mg tan-
ezumab). In addition, nine patients required less urgent joint 
replacement. Histological examination of the bone samples 
suggested simple OA or RPOA as opposed to primary ON. 
Three patients died in the study, all of whom were taking the 
20 mg dose of tanezumab; however, these deaths were adju-
dicated and were not attributed to the study drug.20
The study team determined that tanezumab is an effec-
tive treatment for lower back pain and safety was similar to 
previous tanezumab trials. The 10 mg dose of tanezumab 
seemed to be better tolerated that 20 mg doses, but both 
dosages showed improvement in pain scores and global 
functional assessments. They concluded that this may be an 
efficacious treatment of back pain, while also acknowledging 
safety concerns.20
A 2014 meta analysis by Leite et al summarized anti-
NGF trials in lower back pain.21 Four trials were included in 
the analysis, including the two studies discussed previously. 
This study determined that the studies by Katz et al and Kivitz 
et al were the two highest quality studies and the greatest in 
size, guiding the discussion on anti-NGF therapy. The other 
two trials were of study drugs REGN475 and fulranumab. 
The conclusion of the meta-analysis was that tanezumab 
showed a low to moderate effect for pain relief in this cohort 
and low evidence for global functional improvement of 
lower back pain-related disability.21 It suggested that while 
the findings may be statistically significant, they might 
lack in clinical significance. The authors proposed that the 
rate of adverse effects in these studies were unacceptable for 





the general population, and that its use for lower back pain 
was not recommended.21
Patient perspectives
In the study by Katz et al, most patients reported an improve-
ment of their back pain from baseline with the use of tan-
ezumab. In addition, patients taking the study drug rated 
their back pain more favorably than patients taking both 
naproxen and placebo. At the 6-week mark in this study, a 
larger percentage of patients in the tanezumab group (78.8%) 
classified their back pain as either “very good” or “good” 
compared to the placebo (71.0%) and naproxen groups 
(65.3%). However, this was not measured to be statistically 
significant. Also, at week 6 more patients in the tanezumab 
group (83.1%) gave the study medication a rating of “good” 
or “excellent” opposed to those receiving placebo (58.1%) 
or naproxen (54.7%). This trend was seen for all time points, 
but was only statistically significant at week 6.18
In the Kivitiz et al trial, the overall incidence of early 
withdrawal was lower in all groups treated with tanezumab 
compared to those receiving naproxen or placebo. The 
incidence of premature discontinuation was highest in the 
placebo group (43.8%) and lowest in the tanezumab 10 mg 
group (34.2%). The most cited reason for early withdrawal 
was lack of efficacy. Highest withdrawal rates were seen 
with the placebo group (25.7%) and lowest in those taking 
tanezumab 20 mg (11.5%). Patients receiving 20 mg tan-
ezumab (9.5%) had the highest rate of adverse events and 
study termination because of these particular effects. Those 
receiving naproxen had the lowest rate (3.4%) of discontinua-
tion due to adverse events. All other groups had similar rates 
of withdrawal due to adverse events.19
Conclusion
Chronic lower back pain affects a significant proportion of 
the population, which often results in a significant disease 
burden, lost productivity, and reduced quality of life. Treating 
chronic lower back pain can often prove difficult for provid-
ers, so there is an urgent need for effective pharmacologi-
cal agents. The use of both intravenous and subcutaneous 
tanezumab has shown promise in the treatment of chronic 
lower back pain. There are few studies that have examined 
the efficacy of tanezumab in chronic lower back pain, likely 
because it is a relatively new agent and there have been 
several partial clinical holds placed on the drug.22 One par-
ticular clinical hold was enacted by the FDA because there 
was a concern for the development of ON with tanezumab 
use. After closer investigation, no evidence was found asso-
ciating the use of tanezumab with an increased risk of ON. 
Tanezumab was associated with an increased risk of RPOA, 
especially when higher doses were used and when coadmin-
istered with NSAIDs.17 Tanezumab was also associated with 
a higher risk of adverse effects including myalgia, arthralgia, 
and abnormal peripheral nerve sensations, but this was not 
statistically significant, and there was no increase in serious 
adverse events.22
A single dose of tanezumab may provide analgesic effects 
for up to 12 weeks.18 Doses of 10 mg and 20 mg were shown 
to provide prolonged analgesic effectiveness in addition to 
improvements in physical functioning.21 There appears to 
be no measurable difference in efficacy between 10 mg and 
20 mg doses; however, 10 mg tanezumab appears to be better 
tolerated than the 20 mg dose.20 In the studies examined, there 
was also no statistically significant difference in improve-
ment of chronic lower back pain between 5 mg tanezumab, 
naproxen, and placebo.19 However, there is evidence that 5 
mg of tanezumab can provide measurable improvements 
in physical functioning and pain in patients with OA.23 
A meta-analysis found a small to moderate analgesic effect 
for chronic lower back pain as well as a small increase in 
functional improvement when compared to placebo.21
More studies are needed to better characterize the analge-
sic effects, the impact on quality of life, and the safety profile 
of tanezumab. There are currently two Phase III randomized 
controlled trials underway to further investigate the efficacy 
and safety of tanezumab in the treatment of chronic lower 
back pain. Estimated enrollments for these trials are 390 and 
1,800 patients and both plan to administer either 5 or 10 mg 
of tanezumab subcutaneously every 8 weeks over a 56-week 
period.24,25 The completion of these studies and hopefully 
other trials to come will help to determine the role of tan-
ezumab in the treatment of chronic lower back pain.
Tanezumab is a relatively new therapeutic agent for back 
pain, which may have some positive benefit in the treatment 
of chronic LBP. While there is a small statistically significant 
clinical benefit observed in trials of the drug, there are also 
problematic large numbers of adverse effects associated with 
its use. Due to the high rates of adverse effects and lack of 
long-term data, more evidence is needed before a therapeutic 
role can be clearly defined. Monoclonal antibodies against 
neurotrophic agents represent a new class of drug that war-
rants further exploration of its use as analgesic modality for 
patients with chronic low lack pain.
Acknowledgments
The authors acknowledge the recent passing of Dr Phillip 
J Kadowitz, PhD, Professor at Tulane School of Medicine, 
Department of Pharmacology, and Adjunct Professor at 
Therapeutics and Clinical Risk Management
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/therapeutics-and-clinical-risk-management-journal
Therapeutics and Clinical Risk Management is an international, peer-
reviewed journal of clinical therapeutics and risk management, focusing 
on concise rapid reporting of clinical studies in all therapeutic areas, 
outcomes, safety, and programs for the effective, safe, and sustained 
use of medicines. This journal is indexed on PubMed Central, CAS, 
EMBase, Scopus and the Elsevier Bibliographic databases. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.





Tanezumab for chronic lower back pain
the Louisiana State University Health Science Center, 
Department of Anesthesiology, for his lifelong teaching of 
medical students, graduate students, and residents over a 
50 plus year career. One of his PhD graduate students was 
Dr Alan D Kaye, MD, PhD.
Disclosure
Dr Kaye is a speaker for Depomed, Inc, and Merck. Dr Urman 
has received research funding from Cara Pharmaceuticals, 
Mallinckrodt, Merck, and Medtronic. The other authors 
report no conflicts of interest in this work.
References
 1. Centers for Disease Control and Prevention (CDC). Prevalence of dis-
abilities and associated health conditions among adults – United States, 
1999. MMWR Morb Mortal Wkly Rep. 2001;50(7):120–125.
 2. Simon J, McAuliffe M, Shamim F, Vuong N, Tahaei A. Discogenic 
low back pain. Phys Med Rehabil Clin N Am. 2014;25(2):305–317.
 3. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. 
Global, regional, and national incidence, prevalence, and years lived 
with disability for 310 diseases and injuries, 1990–2015: a system-
atic analysis for the Global Burden of Disease Study 2015. Lancet. 
2016;388(10053):1545–1602.
 4. Frymoyer JW, editor. The Adult Spine: Principles and Practice. 
Philadelphia, PA: Lippincott-Raven; 1997.
 5. Croft P, Rigby AS, Boswell R, Schollum J, Silman A. The prevalence 
of chronic widespread pain in the general population. J Rheumatol. 
1993;20(4):710–713.
 6. Rubin DI. Epidemiology and risk factors for spine pain. Neurol Clin. 
2007;25(2):353–371.
 7. Jarvik JG, Deyo RA. Diagnostic evaluation of low back pain with 
emphasis on imaging. Ann Intern Med. 2002;137(7):586–597.
 8. Lane NE, Schnitzer TJ, Birbara CA, Mokhtarani M, Shelton DL, 
Smith MD, Brown MT. Tanezumab for the treatment of pain from 
osteoarthritis of the knee. N Engl J Med. 2010;363(16):1521–1531.
 9. Abdiche YN, Malashock DS, Pons J. Probing the binding mecha-
nism and affinity of tanezumab, a recombinant humanized anti-NGF 
monoclonal antibody, using a repertoire of biosensors. Protein Sci. 
2008;17(8):1326–1335.
 10. Halliday DA, Zettler C, Rush RA, Scicchitano R, McNeil JD. Elevated 
nerve growth factor levels in the synovial fluid of patients with inflam-
matory joint disease. Neurochem Res. 1998;23(6):919–922.
 11. Zhao L, Ren TH, Wang DD. Clinical pharmacology considerations in bio-
logics development. Acta Pharmacol Sin. 2012;33(11):1339–1347.
 12. Jonsson EN, Xie R, Marshall SF, Arends RH. Population pharmacoki-
netics of tanezumab in phase 3 clinical trials for osteoarthritis pain. 
Br J Clin Pharmacol. 2016;81(4):688–699.
 13. Paul WE. Immunology: structure and function. In: Paul WE. Fundamental 
immunology. 4th ed. Philadelphia, PA: Lippencott-Raven; 1999.
 14. Akilesh S, Huber TB, Wu H, et al. Podocytes use FcRn to clear IgG 
from the glomerular basement membrane. Proc Natl Acad Sci U S A. 
2008;105(3):967–972.
 15. Wang DD, Zhang S, Zhao H, Men AY, Parivar K. Fixed dosing versus 
body size-based dosing of monoclonal antibodies in adult clinical trials. 
J Clin Pharmacol. 2009;49(9):1012–1024.
 16. United States Food and Drug Administration. Tanezumab Arthritis 




 17. Hochberg MC, Tive LA, Abramson SB, et al. When is osteonecrosis not 
osteonecrosis?: adjudication of reported serious adverse joint events in 
the Tanezumab Clinical Development Program. Arthritis Rheumatol. 
2016;68(2):382–391.
 18. Katz N, Borenstein DG, Birbara C, Bramson C, Nemeth MA, Smith MD, 
Brown MT. Efficacy and safety of tanezumab in the treatment of chronic 
low back pain. Pain. 2011;152(10):2248–2258.
 19. Kivitz AJ, Gimbel JS, Bramson C, et al. Efficacy and safety of tan-
ezumab versus naproxen in the treatment of chronic low back pain. 
Pain. 2013;154(7):1009–1021.
 20. Gimbel JS, Kivitz AJ, Bramson C, et al. Long-term safety and effec-
tiveness of tanezumab as treatment for chronic low back pain. Pain. 
2014;155(9):1793–1801.
 21. Leite VF, Buehler AM, El Abd O, et al. Anti-nerve growth factor in 
the treatment of low back pain and radiculopathy: a systematic review 
and a meta-analysis. Pain Physician. 2014;17(1):E45–E60.
 22. Knezevic NN, Mandalia S, Raasch J, Knezevic I, Candido KD. Treat-
ment of chronic low back pain – new approaches on the horizon. J Pain 
Res. 2017;10:1111–1123.
 23. Bannwarth B, Kostine M. Targeting nerve growth factor (NGF) for pain 
management: what does the future hold for NGF antagonists? Drugs. 
2014;74(6):619–626.
 24. Pfizer. A phase 3 study of tanezumab for chronic low back 
pain (TANGO). Available from: https://Clinicaltrials.gov/ct2/
show/NCT02528253. NLM identifier: NCT02528253. Accessed 
February 4, 2018.
 25. Pfizer. Long term safety and efficacy study of tanezumab in Japanese 
adult subjects with chronic low back pain (TANGO). Available from: 
https://clinicaltrials.gov/ct2/show/record/NCT02725411?term=tane
zumab&cond=Chronic+Low-back+Pain&rank=1. NLM identifier: 
NCT02725411. Accessed February 4, 2018.
